Carisoprodol withdrawn

The EMEA has recommended suspension of the marketing authorisation for carisoprodol (Carisoma), a muscle relaxant indicated for treatment of acute musculo-skeletal disorders associated with muscle spasm.

The CHMP has concluded that there is a risk of abuse, addiction, intoxication and psychomotor impairment with carisoprodol and that there are effective alternatives with a better safety profile.

Prescribers should not issue any new prescriptions for carisoprodol and should switch patients taking the medicine to an alternative treatment if necessary

Further information: CHMP

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases